KaNDy Therapeutics Company

KaNDy Therapeutics is a provider of bio-technical research and development services intended to offer treatment for common, chronic debilitating female sex hormone-related conditions. The company's services offer non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment and reduce symptoms of hormone-related conditions.

Last Funding Type: Series C
Total Funding: $32 589 510
Last Funding Date: 2018-08-29
Funding Status: M&A
Number Of Exists: Series C
Employee Number: 1-10
Estimated Revenue: $1M to $10M
Technology: Cancer
Investors Number: 5
Founded Date: 2017
Headquarters: Stevenage, Herefordshire, United Kingdom
Investment Stage: N/A
Industry: Longevity
Investor Type: Company